Appointment sheet
Squamous cell carcinoma of the lung
Prepared with OnCo (onco.cc/prep/lung-squamous-cell-carcinoma/). Orientation, not medical advice; your team knows your case.
My details
Name
Date of appointment
Hospital and clinician
Who is coming with me
What I know, what is unclear, changes to discuss
Saved in this browserWhat I know so far
What is unclear to me
Changes since last time
My questions
13 on the sheetNewly diagnosed
- 1.What is my exact diagnosis, stage, and grade, and which tests established them?
- 2.Which biomarkers have been tested on my tumour (for example p40 and p63 on immunohistochemistry, TTF-1 negative, PD-L1 tumour proportion score, TP53, NFE2L2 and KEAP1 mutations, Driver testing in never-smokers or mixed histology only), and what were the results?
- 3.Which subtype is my cancer, and does that change the recommended treatment?
- 4.Is germline (inherited) genetic testing recommended for me or my family?
Metastatic, first line
- 5.For my situation (metastatic, first line), which of the standard options do you recommend and why?
- 6.Am I a candidate for Pembrolizumab, Carboplatin, Paclitaxel / nab-paclitaxel or related drugs, and what side effects should I expect?
- 7.How do the results of KEYNOTE-407 apply to someone like me?
Metastatic, later lines
- 8.For my situation (metastatic, later lines), which of the standard options do you recommend and why?
- 9.Am I a candidate for Docetaxel, Ramucirumab, Afatinib, and what side effects should I expect?
- 10.How do the results of Lung-MAP (SWOG S1400 and S1900) and Lung-MAP S1400I: nivolumab with or without ipilimumab apply to someone like me?
Early stage
- 11.For my situation (early stage), which of the standard options do you recommend and why?
Any stage
- 12.Would a second opinion at a high-volume centre change anything, and can you help arrange it?
- 13.What supportive care (symptom control, nutrition, exercise, mental health, financial help) is available from the start?
Tests and results to bring
Biomarker results to ask for: p40 and p63 on immunohistochemistry, TTF-1 negative, PD-L1 tumour proportion score, TP53, NFE2L2 and KEAP1 mutations (prognostic, not yet actionable), Driver testing in never-smokers or mixed histology only.
Bring copies of scan reports, pathology and blood results, and a list of every medicine and supplement.
The treatments I may be offered
- Early stage: Treated as the parent's resectable and stage III pages describe. (Resectable stage I to III non-small-cell lung cancer, Unresectable stage III non-small-cell lung cancer)
- Metastatic, first line: Carboplatin with paclitaxel or nab-paclitaxel plus pembrolizumab (KEYNOTE-407); cemiplimab with chemotherapy or the parent's PD-L1-high pathway as alternatives. (KEYNOTE-407, Pembrolizumab, Carboplatin, Paclitaxel / nab-paclitaxel, Nab-paclitaxel, Cemiplimab, PD-L1-high non-small-cell lung cancer without a driver mutation)
- Metastatic, later lines: Docetaxel with or without ramucirumab; afatinib; biomarker-matched drugs through Lung-MAP. (Docetaxel, Ramucirumab, Afatinib, Lung-MAP (SWOG S1400 and S1900), Lung-MAP S1400I: nivolumab with or without ipilimumab)
From the standard of care recorded for this cancer; which apply depends on your stage and biomarkers. Ask which the team recommends and why.
Answers and next steps
Saved in this browserWhat I was told
Agreed next steps, dates and who to call